Wells Fargo & Company Onconova Therapeutics, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.67 - $1.01 $2 - $3	3 Added 1.86%	164 $0
Q4 2023 Feb 09, 2024	BUY	$0.62 - $0.79 $4 - $6	8 Added 5.23%	161 $0
Q3 2023 Nov 13, 2023	BUY	$0.71 - $1.15 $1 - $2	2 Added 1.32%	153 $0
Q2 2023 Aug 15, 2023	BUY	$0.67 - $1.42 $4 - $8	6 Added 4.14%	151 $0
Q1 2023 May 12, 2023	BUY	$0.69 - $1.42 $2 - $4	3 Added 2.11%	145 $0
Q4 2022 Feb 13, 2023	BUY	$0.63 - $0.97 $1 - $2	3 Added 2.16%	142 $0
Q3 2022 Nov 14, 2022	BUY	$0.95 - $1.45 $7 - $11	8 Added 6.11%	139 $0
Q2 2022 Aug 12, 2022	BUY	$1.04 - $1.9 $10 - $19	10 Added 8.26%	131 $0
Q1 2022 May 16, 2022	BUY	$1.46 - $2.82 $1 - $2	1 Added 0.83%	121 $0
Q4 2021 Feb 14, 2022	BUY	$2.49 - $3.73 $69 - $104	28 Added 30.43%	120 $0
Q3 2021 Nov 15, 2021	SELL	$3.81 - $6.76 $41 - $74	-11 Reduced 10.68%	92 $0
Q2 2021 Aug 16, 2021	BUY	$6.28 - $16.2 $646 - $1,668	103 New	103 $1,000

276K

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.